Literature DB >> 30710596

Mendelian randomisation: A powerful and inexpensive method for identifying and excluding non-genetic risk factors for colorectal cancer.

Alex J Cornish1, Ian P M Tomlinson2, Richard S Houlston3.   

Abstract

Colorectal cancer (CRC) is the third most common cancer in economically developed countries and a major cause of cancer-related mortality. The importance of lifestyle and diet as major determinants of CRC risk is suggested by differences in CRC incidence between countries and in migration studies. Previous observational epidemiological studies have identified associations between modifiable environmental risk factors and CRC, but these studies can be susceptible to reverse causation and confounding, and their results can therefore conflict. Mendelian randomisation (MR) analysis represents an approach complementary to conventional observational studies examining associations between exposures and disease. The MR strategy employs allelic variants as instrumental variables (IVs), which act as proxies for non-genetic exposures. These allelic variants are randomly assigned during meiosis and can therefore inform on life-long exposure, whilst not being subject to reverse causation. In previous studies MR frameworks have associated several modifiable factors with CRC risk, including adiposity, hyperlipidaemia, fatty acid profile and alcohol consumption. In this review we detail the use of MR to investigate and discover CRC risk factors, and its future applications.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Causal relationship; Colorectal cancer; Genetic variants; Instrumental variables; Mendelian randomisation; Risk factors

Mesh:

Year:  2019        PMID: 30710596      PMCID: PMC6856712          DOI: 10.1016/j.mam.2019.01.002

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


Introduction

Colorectal cancer (CRC) is one of the most common cancers in economically developed countries and a major cause of cancer-related mortality (Forman et al., 2014). The disease is currently diagnosed in over one million individuals worldwide annually; although its incidence is set to rise in developing countries with the adoption of western lifestyles and diets (Haggar and Boushey, 2009). The importance of lifestyle and diet as major determinants of CRC risk have been strongly suggested by geographical differences in CRC incidence and demonstrated in migration studies (Kamangar et al., 2006). Given the importance of these factors in CRC risk, the modification of lifestyle and diet through public health initiatives offers the prospect of significant impact on CRC incidence. The full compendium of exposures affecting CRC risk, and their relative contributions, has yet to be elucidated however, necessitating further work to discover and validate risk factors.

Established and postulated colorectal cancer risk factors

Both environmental and genetic factors play important roles in CRC aetiology. The majority of CRCs are sporadic, with approximately 80% of patients presenting without a family history of the disease (Winawer et al., 1997). The lifetime risk for CRC in Western populations is approximately 4% (Siegel et al., 2017), although this risk is almost doubled in individuals with a first-degree family member diagnosed with CRC, and tripled in individuals with two or more affected family members (Taylor et al., 2010). Epidemiological studies have provided support for a hereditary component to the aetiology of a large number of cancers, including CRC (Risch, 2001). For many cancers, a higher concordance in monozygotic twins as compared with dizygotic twins, or with siblings, has been observed (Lichtenstein et al., 2000). Whilst such concordance is compatible with inherited genetic variation affecting risk, non-genetic mechanisms cannot be excluded as a basis of the measured heritability. Technological developments in high-throughput genotyping and improved understanding of common genetic variation have made genome-wide association studies (GWAS) possible, facilitating the identification of single nucleotide polymorphisms (SNPs) influencing cancer risk (Sud et al., 2017). So far, GWAS have identified approximately 100 SNPs independently associated with CRC risk (Al-Tassan et al., 2015; Broderick et al., 2007; Cogent Study et al., 2008; Dunlop et al., 2012; Houlston et al., 2010; Kinnersley et al., 2012; Orlando et al., 2016; Schumacher et al., 2015; Tenesa et al., 2008; Tomlinson et al., 2007; Whiffin et al., 2014), with the largest study to-date combining data from over 125,000 individuals (Huyghe et al., 2019). The identification of these risk variants has contributed to an improved understanding of the pathways and mechanisms influencing CRC development. Multiple lifestyle and environmental factors, many of which are modifiable, are now known to influence CRC risk (Kuipers et al., 2015; World Cancer Research Fund, 2017). The World Cancer Research Fund (2017) conducted a systematic analysis of known and suspected CRC risk factors, categorizing them into those with strong and limited evidence for a causal relationship. The evidence that obesity, height, alcohol intake and consumption of red and processed meats increases CRC risk was reported as strong, whilst the evidence that low intake of non-starchy vegetables and fruits, and high intake of foods containing iron increases CRC risk was reported to be weaker. The World Cancer Research Fund report also highlighted physical activity, the consumption of whole grains, fibre, dairy products and the use of calcium supplements as being strongly associated with lower CRC risk, but reported weaker evidence that use of multivitamin supplements, and high intake of foods containing vitamins C and D similarly decreases CRC risk. Increased CRC risk has also been associated with chronic colitis due to inflammatory bowel disease (IBD) (Lu et al., 2018). The longer the duration of IBD, the greater the increase in CRC risk (Lu et al., 2018). However, whilst IBD is thought to increase risk of CRC, it explains only a small proportion of CRC incidence in Western populations (Kuipers et al., 2015). Improved surveillance and the increasing effectiveness of anti-inflammatory treatments may also be lowering the incidence of CRC in those with IBD (Jess et al., 2012). Heavy smoking over a prolonged period has also been recognised as being associated with increased CRC risk, in the region of an additional 11 cases per 100,000 person-years (Botteri et al., 2008). The influence of modifiable environmental and lifestyle risk factors is likely to partly explain the socioeconomic and geographic differences in CRC rates (Doubeni et al., 2012). It has been estimated that as many as 71% of CRCs in Western countries may be due to these modifiable exposures and therefore preventable (Platz et al., 2000). However, to reduce CRC incidence through public health initiatives, it is imperative to determine which factors associated with CRC risk are causally related, and which are simply correlated.

Approaches for risk factor discovery and validation

Observational epidemiological studies

So far, many studies attempting to evaluate relationships between possible risk factors and diseases, such as CRC, have relied upon observational case-control, cohort, or cross-sectional study designs (Lawlor et al., 2004). Whilst observational studies have seemingly robustly associated a risk factor and a disease, interventions modifying such risk factors do not always result in the anticipated change in disease incidence (Davey Smith and Hemani, 2014). A number of explanations for these ostensibly paradoxical observations have been suggested, including the susceptibility of observational epidemiological studies to certain biases, such as reverse causation, confounding and errors in measurement. These biases can result in an apparent association between a risk factor and a disease, without the existence of a direct causal relationship. Reverse causation occurs when the postulated risk factor does not itself influence disease development, but instead the occurrence of the disease affects the postulated risk factor. An example of possible reverse causation is in the relationship between computerized tomography (CT) scans and cancer (Mathews et al., 2013). Higher cancer incidence has been observed in individuals exposed to low-dose ionizing radiation from diagnostic CT scans (Mathews et al., 2013). However, it is difficult to exclude the possibility that the symptoms of precancerous conditions, or early cancer symptoms, led to patients having CT scans. Retrospective studies that seek to establish risk factors after disease diagnosis are especially susceptible to such reverse causation. Confounders are factors causally related to both the postulated risk factor and the disease under consideration. For instance, smoking has been associated with increased risk of CRC (Botteri et al., 2008). However, smoking may be associated with other CRC risk factors, including alcohol consumption, physical inactivity and low uptake of CRC screening (Chao et al., 2000). An individual who consumes more alcohol is indeed more likely to smoke, and if alcohol consumption is causally related to CRC development, then this confounder could partly explain the association between smoking and CRC incidence. Such confounders are not always measured in observational epidemiological studies, and it may therefore not be possible to control for them when evaluating risk factors. Furthermore, unidentified confounders may exist, resulting in additional bias that could be impossible to account for in a traditional observational study design.

Mendelian randomisation

The gold standard for inferring causality is a randomized control trial (RCT). Individuals in an RCT are randomly assigned to two or more groups, minimizing both selection bias and confounding. As groups are assigned at the start of the study, reverse causation can be avoided. RCTs are however often not possible due to the costs or the time required. Furthermore, RCTs can have short follow-up times and hence only reflect the effect of an exposure at a certain time in life. It is also not always possible to assign individuals to groups to evaluate certain risk factors because of practical or ethical concerns. Mendelian randomisation (MR) uses genetic variants, such as SNPs, as proxies for exposures to determine the effect of an exposure on an outcome (Sheehan et al., 2008). In the general population, germline variants tend to be randomly distributed with respect to most human traits. This occurs because of the fixed nature of germline genotypes and Mendel's laws of inheritance (i.e. segregation and independent assortment). Using germline variants as proxies for an exposure therefore ensures that MR is less susceptible to biases that affect many observational epidemiological studies (Davey Smith and Hemani, 2014). For example, as genotypes are randomly assigned at conception, MR is not biased by reverse causation. MR can therefore be considered analogous to a natural RCT. Furthermore, as genotypes are present at conception, MR analyses can examine the lifetime effect of an exposure on disease risk, unlike other study designs. MR analyses involve three main assumptions: (i) the genetic variants used as IVs are robustly associated with the exposure under consideration; (ii) these IVs are independent of confounding factors; and (iii) the IVs are only associated with the outcome under consideration via the exposure (Lawlor et al., 2008). These three assumptions are often depicted as a directed acyclic graph (Fig. 1). The satisfaction of these three assumptions is sufficient to test the null hypothesis that the exposure is not causally related to the outcome. However, to accurately estimate the size of the effect, a fourth additional assumption is required: (iv) all associations depicted in Fig. 1 are unaffected by statistical interactions and are linear (Lawlor et al., 2008). Considering these assumptions, genetic variants can be used as proxies for a large range of modifiable risk factors. In one-sample MR, a single data set containing all information on the genetic variants, the exposure and the outcome for all individuals is used to assess a potential causal relationship (Haycock et al., 2016). In practice, few data sets contain exposure data for all individuals and a sufficient number of disease cases and controls to conduct one-sample MR analyses with sufficient power to identify causal effects. This has prompted the development of two-sample MR strategies, which use data from separate data sets: one containing information on genetic variants and the exposure of interest, and another containing information on the same genetic variants and the considered outcome (Hartwig et al., 2016). For many risk factors and cancers, GWAS containing data from tens or hundreds of thousands of individuals have been completed (Sud et al., 2017), facilitating the use of two-sample MR to study the causal relationship between various exposures and diseases. Resources such as the GWAS Catalog have collated and standardized data from a large number of studies (Buniello et al., 2019), aiding the identification of suitable genetic instruments.
Fig. 1

The basic instrumental variable (IV) model depicted using a directed acyclic graph. Z: the instrumental variable, X: the exposure of interest (such as a putative risk factor), Y: the outcome of interest (such as a disease), U: one or more measured or unmeasured confounders.

The basic instrumental variable (IV) model depicted using a directed acyclic graph. Z: the instrumental variable, X: the exposure of interest (such as a putative risk factor), Y: the outcome of interest (such as a disease), U: one or more measured or unmeasured confounders. One of the central tenets of MR is the absence of pleiotropy (i.e. a variant influencing multiple traits) between the SNPs associated with the exposure and outcome (Davey Smith and Hemani, 2014). Directional pleiotropy can result in the false identification of an association between a putative exposure and outcome, or the failure to identify a true causal relationship (Burgess and Thompson, 2017). Multiple methods have been developed to assess whether such directional pleiotropy exists and avoid it biasing causal estimates. In MR-Egger regression, the slope coefficient from Egger regression is used to assess directional pleiotropy (Bowden et al., 2015). MR-Egger regression relies on the assumption that the pleiotropic effects of each variant are independently distributed from the genetic association with the outcome; an assumption referred to as InSIDE (INstrument Strength Independent of Direct Effect). If the InSIDE assumption is satisfied, then MR-Egger causal effect estimates will be consistent as sample size and the number of genetic variants increase (Burgess and Thompson, 2017). Furthermore, under the InSIDE assumption the MR-Egger intercept term can be used to evaluate the average pleiotropic effect across variants. If this average pleiotropic effect is zero, then the MR-Egger causal effect estimate will equal causal effect estimates from other regression-based MR approaches, including the inverse variance weighted (IVW) method (Burgess and Thompson, 2017). Approaches such as the HEIDI outlier test, implemented as part of the Generalised Summary-data-based Mendelian Randomisation (GSMR) package (Zhu et al., 2018), can also be used to identify and remove variants that violate IV assumptions. Methods such as simple and weighted median estimators (Bowden et al., 2016) and the mode-based estimate (Hartwig et al., 2017) can produce unbiased estimates of a causal effect even when the majority of IVs are invalid. Further methodological developments, such as latent causal variable (LCV) models, allow for accurate inference of causal relationships, even when the exposure and outcome are genetically correlated (O'Connor and Price, 2018). These methods also have their disadvantages however, with MR-Egger, median estimators and mode-based estimates generally achieving less power than conventional IV approaches (Bowden et al., 2015), and LCV models requiring genome-wide summary statistics for both the exposure and outcome – data that are not always available.

Limitations of Mendelian randomisation

Whilst MR analyses complement observational epidemiological studies, and are less influenced by some biases, there are a number of limitations to the approach. MR methods rely on the availability of genetic instruments robustly associated with the exposure of interest that can be used as proxies. For some exposures, such as obesity and height, GWAS containing data from hundreds of thousands of individuals have been completed, resulting in the identification of hundreds of exposure-associated SNPs that explain a high proportion of the genetically associated exposure (Yengo et al., 2018). For other exposures no or few associated SNPs have been identified, thereby prohibiting their study using MR frameworks. If exposure-associated SNPs have been identified, but these SNPs explain only a small proportion of exposure variation, then MR analyses may not be sufficiently powered to detect causal effects, especially if the true effect sizes are weak (Smith and Ebrahim, 2004). The study of some risk factors requires additional information not always available, even when using a two-sample MR framework. For example, different SNPs are associated with smoking initiation and number of cigarettes smoked per day (Tobacco and Genetics Consortium, 2010), and it is therefore necessary to stratify disease cases and controls by whether they have ever smoked to accurately estimate the effect size of smoking on disease risk. In many cancer GWAS, smoking status is not measured, prohibiting the accurate assessment of effect size. Although implemented in a number of studies (Ahmad et al., 2015; Gage et al., 2017), conventional IV approaches in a two-sample setting may not accurately estimate the effect size of a binary exposure, such as smoking initiation, on a binary outcome, such as disease diagnosis. Through simulation we previously evaluated whether IVW, weighted median estimators, mode-base estimates and MR-Egger methods provide reliable estimates of causal effects when considering binary exposures and binary outcomes (Disney-Hogg et al., 2018). When a causal relationship was simulated, the magnitudes of the effect estimates were inflated, and two-sample MR frameworks may therefore not be suitable for assessing the effect size of binary exposures on CRC risk.

Mendelian randomisation in colorectal cancer research

Many studies have implemented two-sample MR frameworks to evaluate causal relationships between risk factors and CRC. Here we discuss findings and insights from these studies (Table 1).
Table 1

MR studies that have assessed a possible causal relationship between exposures and CRC risk.

Risk factorReferenceNumber of CRC casesNumber of controlsPrimary findings using MR
AdiponectinSong et al. (2015)70207631No significant association.
Nimptsch et al. (2017)12531627No significant association.
Pei et al. (2015)NANAInconsistent evidence.
Age at menarche & menopauseNeumeyer et al. (2018)12,94410,741No significant association.
AlcoholWang et al. (2011)23923951Alcohol consumption associated with increased CRC risk (OR: 1.31, 95% CI: 1.01–1.70).
AspirinLin et al. (2002)161219No significant association.
C-reactive protein (CRP)Wang et al. (2018)30,48022,844No significant association.
Nimptsch et al. (2015a)727727CRP concentration associated with increased CRC risk (OR: 1.74, 95% CI: 1.06–2.85).
Fatty acidsMay-Wilson et al. (2017)925418,386Arachidonic acid (OR: 1.05, 95% CI: 1.02–1.07, P = 1.7 × 10−4) and stearic saturated fatty acids (OR: 1.17, 95% CI: 1.01–1.35, P = 0.041) associated with increased CRC risk. Oleic (OR: 0.77, 95% CI: 0.65–0.92, P = 3.9 × 10−3) and palmitoleic (OR: 0.36, 95% CI: 0.15–0.84, P = 0.018) monounsaturated fatty acids, and linoleic polyunsaturated fatty acids (OR: 0.95, 95% CI: 0.93–0.98, P = 3.7 × 10−4) associated with reduced CRC risk.
Fetuin-ANimptsch et al. (2015b)456456No significant association.
HeightThrift et al. (2015a)10,22610,286Height associated with increased CRC risk (OR: 1.07, 95% CI: 1.01–1.14).
Khankari et al. (2016)51004831Height associated with increased CRC risk (OR: 1.58, 95% CI: 1.14–2.18, P = 0.006).
Interleukin-6Tian et al. (2015)10,25712,391No significant association.
LipidsRodriguez-Broadbent et al. (2017)925418,386Higher total cholesterol associated with increased CRC risk (OR: 1.46, 95% CI: 1.20–1.79, P = 1.68 × 10−4). Statin-effect-simulating HMGCR polymorphism associated with reduced CRC risk (OR: 0.69, 95% CI: 0.49–0.99, P = 0.046). No significant associations for low-density lipoprotein, high-density lipoprotein and total triglyceride.
ObesityJarvis et al. (2016)925418,386BMI (OR: 1.23, 95% CI: 1.02–1.49, P = 0.033), childhood obesity (OR: 1.07, 95% CI: 1.03–1.13, P = 0.018) and WHR (OR: 1.59, 95% CI: 1.08–2.34, P = 0.019) associated with increased CRC risk.
Thrift et al. (2015b)10,22610,286BMI associated with increased CRC risk (OR: 1.50, 95% CI: 1.13–2.01).
Gao et al. (2016)51004831Adult BMI (OR: 1.39, 95% CI: 1.06–1.82, P = 0.016) associated with increased CRC risk. Childhood BMI and WHR non-significant.
Telomere lengthTelomeres Mendelian Randomization Collaboration et al. (2017)14,53716,922No significant association.
Zhang et al. (2015)51004831No significant association.
Vitamin DDimitrakopoulou et al. (2017)11,48884,418No significant association.
He et al. (2018)10,72530,794No significant association.
Theodoratou et al. (2012)20012237No significant association.
MR studies that have assessed a possible causal relationship between exposures and CRC risk. Several studies have investigated the causal relationship between obesity-related factors and CRC risk. In a study of 9254 CRC cases and 18,386 controls, Jarvis et al. (2016) associated body mass index (BMI) (OR: 1.23, 95% CI: 1.02–1.49, P = 0.033), childhood obesity (OR: 1.07, 95% CI: 1.03–1.13, P = 0.018) and waist-hip ratio (WHR) (OR: 1.59, 95% CI: 1.08–2.34, P = 0.019) with increased CRC risk. Gao et al. (2016) similarly associated adult BMI with increased CRC risk (OR: 1.39, 95% CI: 1.06–1.82, P = 0.016), but did not find significant associations for childhood BMI or WHR, possibly due to the smaller size of their study, which contained 5100 CRC cases and 4831 controls. Many obesity-related traits have strong genetic correlations (Bulik-Sullivan et al., 2015) and further work is therefore necessary to investigate which aspects of adiposity have the greatest influence on CRC risk. It has been suggested that adiponectin, an adipocyte-derived peptide hormone, may mediate the association between obesity and risk of CRC (Vansaun, 2013). Observational epidemiological studies of adiponectin have however yielded inconsistent results, with some associating lower circulating adiponectin with increased CRC risk (Aleksandrova et al., 2012), and others failing to identify such association (Stocks et al., 2008). MR analyses of adiponectin and CRC risk have also been inconsistent. In a multi-ethnic meta-analysis, Pei et al. (2015) considered five ADIPOQ polymorphisms, finding the genotype of one (rs2241766) to be associated with CRC risk (OR: 1.26, 95% CI: 1.09–1.47, P = 0.002). Nimptsch et al. (2017) created an ADIPOQ allele score explaining approximately 3% of the variation in circulating adiponectin, but did not find this to be significantly associated with CRC risk. Song et al. (2015) considered 19 adiponectin-associated SNPs and similarly did not find any to be significantly associated with the risk of CRC. Inconsistencies between the observational epidemiological and MR studies could be due to reverse causation or confounding factors biasing the observational studies, or because of the relatively low power of the MR analyses to identify a causal relationship. Hyperinsulinemia has also been suggested to be associated with increased risk of CRC. Nimptsch et al. (2015b) therefore used an MR framework to investigate whether fetuin-A, a liver protein known to inhibit the action of insulin, was causally related to CRC risk. No significant association was identified, although the analysis contained only 456 case-control pairs, and a small effect of fetuin-A on CRC risk therefore cannot be excluded. Development of CRC has been positively correlated with circulating levels of plasma cholesterol and other components of the lipid profile in prospective epidemiological studies (Yao and Tian, 2015). It is not clear however whether these findings reflect a causal relationship or are the consequence of confounding by factors such as a common aetiology of both hyperlipidaemia and CRC. Lipid levels can be modified by both treatment with statins and lifestyle changes and an understanding of the causal relationship with CRC is therefore important when developing CRC prevention programs. The effect of statins, which reduce circulating cholesterol levels, on CRC risk is highly controversial, with a recent meta-analysis of eight RCTs failing to identify a significant beneficial effect (Lytras et al., 2014). Other analyses have however associated statin usage with lower CRC incidence (Mamtani et al., 2016). Rodriguez-Broadbent et al. (2017) employed MR frameworks to study the effects of blood levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) on CRC risk. Higher concentrations of TC were associated with an increased risk of CRC (OR: 1.46, 95% CI: 1.20–1.79, P = 1.68 × 10−4). Furthermore, a genetic risk score for HMGCR, simulating the effect of statins, was associated with reduced CRC risk (OR: 0.69, 95% CI: 0.49–0.99, P = 0.046) (Rodriguez-Broadbent et al., 2017). This study therefore supports a causal relationship between TC and CRC risk, providing further evidence that statin use could be effective in public health strategies aiming to reduce CRC incidence. Dietary fat has been implicated as a cancer risk factor, with meta-analyses of epidemiological studies tending to associate higher consumption of red and processed meat with increased CRC risk (Aykan, 2015). It is unlikely however that the relationship between fat intake and CRC risk depends solely on the quantity, but also on the specific fatty acid (FA) type. Epidemiological studies and animal models have implicated animal fat (Reddy, 2002), some omega-6 polyunsaturated fatty acids (PUFAs) and saturated fatty acid (SFA) with increased cancer risk, and omega-3 PUFA consumption with reduced cancer risk (Azrad et al., 2013). The evidence of a causal relationship between the consumption of specific fatty acids from observational epidemiological studies has however been inconclusive. Possible reasons for this include reverse causation, confounding factors and inaccurate measurement of long-term diet (Theodoratou et al., 2007). Results from an MR study by May-Wilson et al. (2017) were broadly consistent with a pro-inflammatory FA profile having a detrimental effect on risk of CRC. Arachidonic acid (OR: 1.05, 95% CI: 1.02–1.07, P = 1.7 × 10−4) and stearic saturated FAs (OR: 1.17, 95% CI: 1.01–1.35, P = 0.041) were associated with increased CRC risk, whilst oleic (OR: 0.77, 95% CI: 0.65–0.92, P = 3.9 × 10−3) and palmitoleic (OR: 0.36, 95% CI: 0.15–0.84, P = 0.018) monounsaturated FAs, and linoleic polyunsaturated FAs (OR: 0.95, 95% CI: 0.93–0.98, P = 3.7 × 10−4) were associated with reduced CRC risk. In the analysis by May-Wilson et al. (2017), the same SNP (rs102275), or a correlated SNP (rs174547), was used to infer causal relationships between multiple FAs and risk of CRC. These SNPs were used assuming that the exposure individually accounts for the effect on CRC, and the effect of the genetic variant on CRC risk is therefore counted twice, in that it is assigned to multiple FA exposures (Holmes et al., 2017). Consequently, such single locus MR analyses are unable to determine which FA primarily drives the relationship between FA profile and CRC risk. Chronic inflammation has been identified as a risk factor for CRC (Grivennikov, 2013). Higher concentrations of C-reactive protein (CRP), a marker of inflammation, have been associated with an increased risk of CRC in observational epidemiological studies (Tsilidis et al., 2008). Considering only observational studies it is unclear however whether this relationship is causal, or a result of confounding factors. Wang et al. (2018) conducted the largest MR analysis of CRP concentration and CRC risk to-date, and failed to find evidence that CRP concentrations are causally related to risk of CRC. Nimptsch et al. (2015a) conversely found a positive relationship between CRP concentrations and CRC risk (OR: 1.74, 95% CI: 1.06–2.85). However, the study by Nimptsch et al. (2015a) considered only 727 CRC cases and 727 controls, whilst Wang et al. (2018) used data from 30,480 CRC cases and 22,844 controls. This suggests that the causal relationship reported by Nimptsch et al. (2015a) may be a false positive. Numerous studies have associated height with increased risk of cancers, including breast, CRC, leukemia, non-Hodgkin lymphoma and malignant melanoma (Green et al., 2011). GWAS of height encompassing more than half a million individuals have been conducted, identifying SNPs that explain a substantial proportion of height variation (Yengo et al., 2018), and MR frameworks are therefore well suited to investigate the causal relationship between height and CRC. Using data from 10,226 CRC cases and 10,286 controls, Thrift et al. (2015a) found a positive association between height and CRC risk (OR: 1.07, 95% CI: 1.01–1.14). In a smaller study of 5100 cases and 4831 controls, Khankari et al. (2016) also reported a positive association (OR: 1.58, 95% CI: 1.14–2.18, P = 0.006). Epidemiological studies of the effect of reproductive factors on risk of CRC have not been consistent (Martinez et al., 1997; Tsilidis et al., 2010). Neumeyer et al. (2018) employed MR frameworks to study the effect of age at menarche and age at menopause on CRC risk, using data from 12,944 women diagnosed with CRC, and 10,741 women without CRC, identifying no significant associations. The SNPs used as IVs for these reproductive factors explain only a small proportion of their variance however, and therefore although this study used data from a large number of CRC cases and controls, it had limited power to detect weak causal effects. Nevertheless, these results suggest that it is unlikely that age at menarche and menopause have substantial causal effects on CRC risk. Polymorphisms altering the conversion rates of alcohol-metabolizing enzymes, leading to a build-up of excess acetaldehyde and thereby reducing heavy alcohol use, are prevalent in certain Asian populations (Eng et al., 2007). These polymorphisms, such as Glu487Lys in ALDH2, therefore offer the opportunity to use MR frameworks to investigate the effect of alcohol consumption on various traits. Wang et al. (2011) conducted a meta-analysis of MR studies using the Glu487Lys polymorphism to examine the relationship between alcohol consumption and risk of CRC, finding higher genetically predicted alcohol intake to be associated with increased CRC risk (OR: 1.31, 95% CI: 1.01–1.70). The lower frequency of these enzyme-altering alleles in non-Asian populations limits the use of MR to study risk factors in other groups. Large projects such as UK Biobank, which has genotyped SNPs and collected data on alcohol consumption in approximately 500,000 individuals (Bycroft et al., 2018), have led to the identification of SNPs associated with alcohol intake common in other populations (Clarke et al., 2017). Additional alcohol-associated SNPs will facilitate the wider use of MR frameworks to study the effect of alcohol consumption on disease risk. Dimitrakopoulou et al. (2017) used an MR strategy to investigate the relationship between vitamin D and the risk of seven cancers, including CRC, employing SNPs associated with circulating 25-hydroxyvitamin D (25-OHD) as IVs. The analysis found little evidence that vitamin D was associated with increased risk of any of the cancers. He et al. (2018) and Theodoratou et al. (2012) both also similarly found non-significant associations between circulating 25-OHD and CRC risk. These data do not support the results of observational epidemiological studies, which have found circulating 25-OHD to be associated with decreased CRC risk (Ma et al., 2011), suggesting that the observational studies could be biased by reverse causality or confounding factors. Interleukin-6 (IL-6) is thought to influence the progression of several forms of cancer (Kumari et al., 2016). An MR analysis of circulating IL-6 concentrations and cancer risk was performed by Tian et al. (2015), who did not find evidence of a causal relationship. This is concordant with the results of observational epidemiological studies, which have also not identified IL-6 concentrations to be associated with CRC risk (Zhou et al., 2014). One of the earliest studies to use an MR framework to investigate CRC risk factors was conducted by Lin et al. (2002), who used a polymorphism in PTGS2 (Val511Ala) to simulate the effects of aspirin, and thereby study the relationship between aspirin use and CRC risk. Non-significant negative associations between the aspirin-simulating allele and CRC risk were reported, although the study sample sizes were small. The Val511Ala polymorphism is not common in some populations, including Chinese, Japanese and Caucasians, prohibiting its study in many large GWAS data sets based on these ethnicities (Lin et al., 2002). The causal relevance of telomere length to various cancers has also been interrogated using MR frameworks. Whilst two MR studies found genetically predicted longer telomeres to be associated with increased risk of some cancers, including glioma and lung, no association with CRC risk was identified (Telomeres Mendelian Randomization Collaboration et al., 2017; Zhang et al., 2015). Retrospective observational studies of telomere length and CRC found individuals diagnosed with CRC to have shorter telomeres (Pooley et al., 2010), whilst a prospective study identified no significant association between telomere length and CRC diagnosis (Zee et al., 2009). The results from the prospective study and MR studies suggest that the inverse relationship identified in the retrospective study is likely due to reverse causation (Fernandez-Rozadilla et al., 2018; Pooley et al., 2010).

Future uses of Mendelian randomisation

Whilst MR has provided supporting evidence for a number of known and suspected CRC risk factors (Table 1), there are many other putative CRC risk factors that have not yet been interrogated using MR frameworks, including coffee consumption and intake of foods containing calcium, iron or zinc (World Cancer Research Fund, 2017). For some exposures, a lack of associated SNPs explaining a substantial proportion of variance prevents their consideration. As GWAS sample sizes continue to increase, the number of exposures for which there is sufficient power to identify small or moderate effect sizes under an MR framework will grow. So far, MR analyses of CRC risk have generally been hypothesis-driven (i.e. have considered exposures for which there is pre-existing evidence for an effect on CRC risk). Hypothesis-free MR has the potential to identify previously unsuspected risk factors not considered in observational epidemiological studies (Evans and Davey Smith, 2015). Tools such as MR-Base (Hemani et al., 2018), which provides MR method implementations and databases of collated GWAS summary statistics, could help facilitate such hypothesis-free scans. The development and application of additional techniques will also help robustly infer causality between exposures and CRC risk, whilst avoiding biases that can lead to false positives. GSMR improves upon the power of other summary-data-based MR methods by accounting for linkage disequilibrium between SNPs (Zhu et al., 2018), thereby avoiding the unnecessary loss of information. LCV models can identify causal relationships between genetically correlated traits, mediating such correlations with latent causal variables (O'Connor and Price, 2018). This reduces the number of false positives that can occur when using other summary-data-based MR approaches with genetically correlated traits (O'Connor and Price, 2018).

Conclusion

Mendelian randomisation has provided evidence supporting, and not supporting, the causal relationship between multiple risk factors and CRC. Further study using MR frameworks will help inform public health strategies, as well as provide better understanding of CRC aetiology.
  97 in total

Review 1.  Mendelian randomization: prospects, potentials, and limitations.

Authors:  George Davey Smith; Shah Ebrahim
Journal:  Int J Epidemiol       Date:  2004-02       Impact factor: 7.196

2.  Colorectal cancer screening: clinical guidelines and rationale.

Authors:  S J Winawer; R H Fletcher; L Miller; F Godlee; M H Stolar; C D Mulrow; S H Woolf; S N Glick; T G Ganiats; J H Bond; L Rosen; J G Zapka; S J Olsen; F M Giardiello; J E Sisk; R Van Antwerp; C Brown-Davis; D A Marciniak; R J Mayer
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

Review 3.  Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies.

Authors:  Theodore Lytras; Georgios Nikolopoulos; Stefanos Bonovas
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

4.  Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men.

Authors:  E A Platz; W C Willett; G A Colditz; E B Rimm; D Spiegelman; E Giovannucci
Journal:  Cancer Causes Control       Date:  2000-08       Impact factor: 2.506

5.  Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies.

Authors:  Xu Yao; Zhong Tian
Journal:  Cancer Causes Control       Date:  2014-12-09       Impact factor: 2.506

6.  Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer.

Authors:  Richard S Houlston; Emily Webb; Peter Broderick; Alan M Pittman; Maria Chiara Di Bernardo; Steven Lubbe; Ian Chandler; Jayaram Vijayakrishnan; Kate Sullivan; Steven Penegar; Luis Carvajal-Carmona; Kimberley Howarth; Emma Jaeger; Sarah L Spain; Axel Walther; Ella Barclay; Lynn Martin; Maggie Gorman; Enric Domingo; Ana S Teixeira; David Kerr; Jean-Baptiste Cazier; Iina Niittymäki; Sari Tuupanen; Auli Karhu; Lauri A Aaltonen; Ian P M Tomlinson; Susan M Farrington; Albert Tenesa; James G D Prendergast; Rebecca A Barnetson; Roseanne Cetnarskyj; Mary E Porteous; Paul D P Pharoah; Thibaud Koessler; Jochen Hampe; Stephan Buch; Clemens Schafmayer; Jurgen Tepel; Stefan Schreiber; Henry Völzke; Jenny Chang-Claude; Michael Hoffmeister; Hermann Brenner; Brent W Zanke; Alexandre Montpetit; Thomas J Hudson; Steven Gallinger; Harry Campbell; Malcolm G Dunlop
Journal:  Nat Genet       Date:  2008-11-16       Impact factor: 38.330

7.  Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk.

Authors:  Jane Green; Benjamin J Cairns; Delphine Casabonne; F Lucy Wright; Gillian Reeves; Valerie Beral
Journal:  Lancet Oncol       Date:  2011-07-22       Impact factor: 41.316

Review 8.  Current evidence linking polyunsaturated Fatty acids with cancer risk and progression.

Authors:  Maria Azrad; Chelsea Turgeon; Wendy Demark-Wahnefried
Journal:  Front Oncol       Date:  2013-09-04       Impact factor: 6.244

9.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator.

Authors:  Jack Bowden; George Davey Smith; Philip C Haycock; Stephen Burgess
Journal:  Genet Epidemiol       Date:  2016-04-07       Impact factor: 2.135

10.  Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.

Authors:  Sebastian May-Wilson; Amit Sud; Philip J Law; Kimmo Palin; Sari Tuupanen; Alexandra Gylfe; Ulrika A Hänninen; Tatiana Cajuso; Tomas Tanskanen; Johanna Kondelin; Eevi Kaasinen; Antti-Pekka Sarin; Johan G Eriksson; Harri Rissanen; Paul Knekt; Eero Pukkala; Pekka Jousilahti; Veikko Salomaa; Samuli Ripatti; Aarno Palotie; Laura Renkonen-Sinisalo; Anna Lepistö; Jan Böhm; Jukka-Pekka Mecklin; Nada A Al-Tassan; Claire Palles; Susan M Farrington; Maria N Timofeeva; Brian F Meyer; Salma M Wakil; Harry Campbell; Christopher G Smith; Shelley Idziaszczyk; Timothy S Maughan; David Fisher; Rachel Kerr; David Kerr; Michael N Passarelli; Jane C Figueiredo; Daniel D Buchanan; Aung K Win; John L Hopper; Mark A Jenkins; Noralane M Lindor; Polly A Newcomb; Steven Gallinger; David Conti; Fred Schumacher; Graham Casey; Lauri A Aaltonen; Jeremy P Cheadle; Ian P Tomlinson; Malcolm G Dunlop; Richard S Houlston
Journal:  Eur J Cancer       Date:  2017-08-19       Impact factor: 10.002

View more
  4 in total

1.  Identifying Novel Causes of Cancers to Enhance Cancer Prevention: New Strategies Are Needed.

Authors:  Paul Brennan; George Davey-Smith
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 13.506

2.  Association between ALDH2 and ADH1B Polymorphisms and the Risk for Colorectal Cancer in Koreans.

Authors:  Chang Kyun Choi; Min-Ho Shin; Sang-Hee Cho; Hye-Yeon Kim; Wei Zheng; Jirong Long; Sun-Seog Kweon
Journal:  Cancer Res Treat       Date:  2020-12-24       Impact factor: 4.679

3.  Modifiable pathways for colorectal cancer: a mendelian randomisation analysis.

Authors:  Alex J Cornish; Philip J Law; Maria Timofeeva; Kimmo Palin; Susan M Farrington; Claire Palles; Mark A Jenkins; Graham Casey; Hermann Brenner; Jenny Chang-Claude; Michael Hoffmeister; Iva Kirac; Tim Maughan; Stefanie Brezina; Andrea Gsur; Jeremy P Cheadle; Lauri A Aaltonen; Ian Tomlinson; Malcolm G Dunlop; Richard S Houlston
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-10-24

4.  Systematic review of Mendelian randomization studies on risk of cancer.

Authors:  Georgios Markozannes; Afroditi Kanellopoulou; Olympia Dimopoulou; Dimitrios Kosmidis; Xiaomeng Zhang; Lijuan Wang; Evropi Theodoratou; Dipender Gill; Stephen Burgess; Konstantinos K Tsilidis
Journal:  BMC Med       Date:  2022-02-02       Impact factor: 11.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.